Clinical trials: Healthy Humans
Chronic Hepatitis B
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
This is the first in human study of 162, and the primary objective is to evaluate the safety and tolerability of 162 with a single ascending dose in healthy adult subjects.
- Trial name
- NCT05310487
- Testing
- 162
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yangshengtang Co., Ltd
Pulmonary Disease, Chronic Obstructive
First Time in Human Study With GSK1325756
This study aims to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, oral ascending doses, and repeat oral doses of GSK1325756 administered to healthy adult male volunteers.
- Trial name
- NCT01209052
- Testing
- GSK1325756
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily.
- Trial name
- NCT01287858
- Testing
- AC430
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Healthy Participants
Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study
This study will examine how breathing wildfire-related air pollution (WRAP) for one hour affects healthy adults. The main question the study will answer if the effect of WRAP exposure on p-tau, a blood marker of cognitive…
- Trial name
- WRAP (NCT07151235)
- Testing
- Simulated wildfire smoke exposure, Clean Air exposure
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Paroxysmal Nocturnal Hemoglobinuria
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
Primary objective The tolerability and safety of SAR443809 Secondary The PK parameters of SAR443809 The PD activity of SAR443809 The immunogenicity of SAR443809
- Trial name
- NCT06326814
- Testing
- Humanized anti-Factor Bb monoclonal antibody
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Human
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody…
- Trial name
- NCT06028347
- Testing
- sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seqirus
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects.
- Trial name
- NCT03811678
- Testing
- Kangdaprevir Sodium Tablet
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
SAD and MAD Study With IV and SC Doses of ARGX-117
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117…
- Trial name
- ARGX-117 (NCT04532125)
- Testing
- ARGX-117, ARGX-117 + rHuPH20, ARGX-117 PH20 SC
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- argenx
Hepatitis B, Healthy
First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection
This is a Phase 1, first in human study of ChAdOx1-HBV. The study will be conducted in 40 healthy participants and 12 participants with CHB and virally suppressed with oral antiviral medication.
- Trial name
- NCT04297917
- Testing
- ChAdOx1-HBV
- Where
- 4 sites in United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Infection, Human Immunodeficiency Virus
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5 days (Treatment A) followed by a washout period. In Period 2, subjects will receive GSK2248761 200mg once daily for 5 days (Treatment B).
- Trial name
- NCT01101893
- Testing
- Raltegravir, GSK2248761, GSK2248761 + Raltegravir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
CAB is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment and prevention of human immunodeficiency virus-1 (HIV-1) infection.
- Trial name
- NCT02411435
- Testing
- CAB, RIF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hypovolemia, Fluid Loss
Acetated Ringer´s Solution in Experimental Hypovolemia
Intravenous fluids are often given to increase stroke volume and thereby improve global oxygen delivery. The effect is however often transient, but the effect of a fluid bolus on stroke volume and other hemodynamic variables over…
- Conditions
- Hypovolemia, Fluid Loss, Hemodynamic Instability
- Trial name
- Volu-Flow (NCT05705115)
- Testing
- Ringer acetate, Lower body negative pressure
- Where
- Norway
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Healthy Humans
Immune Benefits From Mushroom Consumption
The purpose of this study is to determine whether consuming mushrooms is effective in enhancing the function of γδ T cells.
- Trial name
- NCT01398176
- Testing
- 3 ounces of mushrooms, 6 ounces of mushrooms
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Florida
SARS-CoV-2 Infection
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 40 Years of Age
- Trial name
- NCT06492564
- Testing
- SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvivo
Healthy Volunteers
First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants
This is a Phase 1, first-in-human study involving single and multiple oral doses of TS-161 in healthy male and female participants. The safety, tolerability, pharmacokinetics and pharmacodynamics of TS-161 will be evaluated.
- Trial name
- NCT03919409
- Testing
- TS-161
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Healthy Young Male Volunteers, Non Athletes
Study of Effects of Low Level Laser Therapy in the Physical Training and the Muscle Responses in Humans.
The hypothesis of this study is that a chronic program of physical strength training, associates to effects of low level laser therapy (LLLT) can, possibly, provide changes in genic expression of muscle and to promote an…
- Conditions
- Healthy Young Male Volunteers, Non Athletes, Free of Metabolic Disease, Joint, Bone and Muscles of Lower Limbs Free of Any Disease
- Trial name
- NCT01113021
- Testing
- Photon stimulation by low level laser therapy
- Where
- Brazil
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universidade Federal de Sao Carlos
Hepatitis C, Chronic
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01928147
- Testing
- PPI-383
- Where
- 6 sites in Mauritius, United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Healthy Participants
A Study of S-740792 in Healthy Adult Study Participants
This is a 3-part study of S-740792 in healthy adult participants. Part 1 (single-ascending-dose and food effect) will investigate the safety, tolerability, and pharmacokinetics (PK) of S-740792.
- Trial name
- NCT06724978
- Testing
- S-740792 Suspension, Midazolam, S-740792 Tablet
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Shionogi
Healthy, Immunisation Against Streptococcus Pneumoniae
Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers
Virometix AG, is conducting research into a vaccine (V-212) to prevent pneumococcal disease, which is any type of illness caused by infection with a bacterium called Streptococcus pneumoniae (S. pneumoniae).
- Trial name
- NCT06975319
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virometix
Healthy Adult Subjects
A Study on the Safety, Tolerability and Pharmacokinetics of WS-0101 Tablets in Chinese Healthy Subjects
This study is an open-label, placebo-controlled, first-in-human clinical trial in healthy adults, designed to assess the safety, tolerability, and PK characteristics of various doses of WS-0101 following different light power…
- Trial name
- NCT06857799
- Testing
- Light Power Density and Light Duration 40 mW/cm²*1000s, Light Power Density and Light Duration 80 mW/cm²*1000s
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital